Neoplasms

All Conditions

Nervous System Diseases

Gland and Hormone Related Diseases

Musculoskeletal Diseases

Rare Diseases

Glioma

Brain Neoplasms

Meningioma

Adenoma

Pituitary Diseases

Skull Base Neoplasms

Skull Neoplasms

Pituitary Neoplasms

Central Nervous System Neoplasms

Nervous System Neoplasms

Brain Diseases

Central Nervous System Diseases

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Hypothalamic Diseases

Endocrine System Diseases

Neoplasms, Nerve Tissue

Neoplasms, Vascular Tissue

Meningeal Neoplasms

Endocrine Gland Neoplasms

Hypothalamic Neoplasms

Supratentorial Neoplasms

Primary brain and skull-base tumors who are amenable for radiotherapy (photon or proton therapy) will all be examined with neurocognitive tests, questionnaires and advanced MR imaging

Primary brain tumour patients will be evaluated longitudinally at the following timepoints: baseline (minimal 4 weeks after surgery, before radiotherapy), three months after end of radiotherapy, 1 year after end of radiotherapy and 2 years after end of radiotherapy. At each visit, neurocognitive testing, a self-report inventory and/or advanced MR imaging will take place.

Time points: baseline, 12 months post-radiotherapy and 24 months post-radiotherapy

Neurocognitive tests: WAIS digit span, HVLT-R, COWAT, MOCA, WAIS digit symbol substitution, TMT A&B, Stroop Color Word Test

Advanced MRI: all participants will be scanned on a 3T Siemens of Philips MR scanner (multicenter protocol): MPRAGE, FLAIR, T2, DWI, rsfMRI, SWI \& ASL

Time points: baseline, 3 months post-radiotherapy and 12 months post-radiotherapy

Time points: baseline, 12 months post-radiotherapy and 24 months post-radiotherapy

Questionnaires: EORTC QLQ C30 & BN20, STAI, CFQ, BDI-II, BRIEF-A, FACIT-F, PSQI

During and after radiotherapy and at at the end of the study, adverse events will be monitored using CTCAEv5.0.

Toxicity scoring

Laurien De Roeck, MD

Maarten Lambrecht, MD PhD

Tom Boterberg, MD PhD

Katrien Erven, MD PhD

The goal of this multicenter prospective longitudinal study is to study the long-term impact of multimodal treatment (chemotherapy, radiotherapy and surgery) in adult brain and base of skull tumors on neurocognitive functioning.

All included patients will complete a self-report inventory (subjective cognitive functioning, QoL, confounders), a cognitive test battery, an advanced MR at multiple timepoints. Moreover, toxicity will be scored according to the CTCAEv5.0 in these patients over time.

This study will combine MR imaging techniques together with elaborate neuropsychological assessments and RT dosimetry in 120 patients who will be examined baseline (before RT) and followed longitudinally after RT.

The first objective is to build an NTCP model for neurocognitive decline after RT (for each cognitive domain separately), linking dose-volume parameters to structures within the brain susceptible to neurological damage and neurocognitive decline after radiotherapy. These NTCP models can be used to make predictions on neurocognitive decline in future primary brain tumour patients receiving cranial RT.

The second objective is to evaluate dose-dependent neurocognitive decline. In particular, the investigators will assess:

* Prevalence and severity of neurocognitive decline after RT for all cognitive domains
* Brain structures or functional brain connections important in neurocognitive functioning (based on dedicated MRI).
* Dose-dependencies of specific neurocognitive skills after RT in adult brain tumour patients
* Correlations between RT dosimetry and early brain changes (MRI)

Neurocognition After Radiotherapy in CNS- and Skull-base Tumors

Neurocognition After Radiotherapy in Adult Brain and Base of Skull Tumors

Construct NTCP models to predict neurocognitive decline based on RT dosimetric and other explanatory variables (gender, age at diagnosis, comorbidities, level of education, social factors such as social activity and occupation, tumour size and localization, pathological/genetic/molecular characteristics, therapy protocols (surgery, radiotherapy and/or chemotherapy)) in an NTCP model for each cognitive domain

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Neurocognition After Radiotherapy in CNS- and Skull-base Tumors	NCT05727605	Cognition Brain Tumor Magnetic Resona... Meningioma Glioma Pituitary Adeno...	Neurocognitive ... MRI Questionnaires:... Toxicity scorin...	18 Years -	Universitaire Ziekenhuizen KU Leuven
Neurocognition After Radiotherapy in CNS- and Skull-base Tumors	NCT05727605	Cognition Brain Tumor Magnetic Resona... Meningioma Glioma Pituitary Adeno...	Neurocognitive ... MRI Questionnaires:... Toxicity scorin...	18 Years -	Universitaire Ziekenhuizen KU Leuven

Spots Global Cancer Trial Database for toxicity scoring